The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

351–375 of 470

  • SevereFDA (Drugs)·D-633-2015·2015-04-29

    Attix Pharmaceuticals Recalls Diphenylcyclopropenone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling diphenylcyclopropenone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Diphenylcyclopropenone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-953-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-546-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bovine Insulin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Bovine Insulin active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Bovine Insulin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-727-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ibuprofen Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling ibuprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ibuprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-785-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methotrexate Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methotrexate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methotrexate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-493-2015·2015-04-29

    Attix Pharmaceuticals Recalls 2-Deoxy-D-Glucose Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2-Deoxy-D-Glucose active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2-Deoxy-D-Glucose active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, On
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-761-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levothyroxine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levothyroxine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levothyroxine Sodium (T4) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-772-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mebendazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mebendazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mebendazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-832-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paromomycin Sulphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Paromomycin Sulphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Paromomycin Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-804-2015·2015-04-29

    Mitotane API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mitotane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mitotane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-499-2015·2015-04-29

    Acetazolamide API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Acetazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Acetazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-534-2015·2015-04-29

    Baclofen API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Baclofen active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Baclofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-705-2015·2015-04-29

    Attix Pharmaceuticals Recalls Histamine Diphosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Histamine Diphosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Histamine Diphosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-766-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-672-2015·2015-04-29

    Attix Pharmaceuticals Recalls Famotidine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling famotidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Famotidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-530-2015·2015-04-29

    Avanafil API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling all lots of Avanafil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Avanafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-851-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Phosphate Monobasic Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Phosphate Monobasic distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Potassium Phosphate Monobasic pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-911-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-930-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-947-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ursodiol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ursodiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ursodiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-743-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ketorolac Tromethamine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Ketorolac Tromethamine active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Ketorolac Tromethamine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-531-2015·2015-04-29

    Attix Pharmaceuticals Recalls Azatadine Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Azatadine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Azatadine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-820-2015·2015-04-29

    Attix Pharmaceuticals Recalls Norethindrone Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Norethindrone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Norethindrone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-931-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tizanidine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tizanidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tizanidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-811-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naftifine HCl Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Naftifine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Naftifine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide